stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Debt to equity
Maravai LifeSciences Holdings, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.5×, down 0.3× from fiscal 2025 (0.9×). Over the past ten years it has ranged from 0.6× (fiscal 2024) to 3.8× (fiscal 2020); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.9× | 52.44% |
| FY2024 | 0.6× | (19.52%) |
| FY2023 | 0.7× | 20.84% |
| FY2022 | 0.6× | (40.12%) |
| FY2021 | 1.0× | (74.52%) |
| FY2020 | 3.8× | 41.50% |
| FY2019 | 2.7× | 17.49% |
| FY2018 | 2.3× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.5× | 4.41% |
| Jun 2026 | 0.5× | (32.29%) |
| Mar 2026 | 0.7× | (15.03%) |
| Dec 2025 | 0.9× | 15.39% |
| 25 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | 0.0× |
| VIR Vir Biotechnology, Inc. compare | 0.0× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.0× |
| MAZE Maze Therapeutics, Inc. compare | 0.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 0.1× |
| MESO Mesoblast Limited compare | 0.2× |
| MRVI Maravai LifeSciences Holdings, Inc. | 0.5× |
| SRPT Sarepta Therapeutics, Inc. compare | 0.6× |
| REPL Replimune Group, Inc. compare | 0.6× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)